Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]3F4AP for Demyelination Imaging
NCT06999434Phase 1Recruiting
- Sponsor
- Yale University
- Start
- May 2025
- Primary completion
- May 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of F-18 3F4AP in demyelinating disorders, Mild Cognitive Impairment (MCI), Alzheimer's disease (AD) and 3 more (6 arms), sponsored by Yale University. Primary endpoints: Tracers volume of distribution at 5 years, Distribution volume ratio at 5 years and 6 more. Started May 2025; status: recruiting.
02
Drugs
F-18 3F4AP
03
Conditions
demyelinating disordersMild Cognitive Impairment (MCI)Alzheimer's disease (AD)multiple sclerosis (MS)spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT06999434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06999434.